Covalon gets European patents for drug delivery via therapeutic hydrogels

By E. Janene Geiss

Philadelphia, Feb. 28 - Covalon Technologies Ltd. said Monday that it has received notice that patents have been issued in France, Germany and the United Kingdom for its technology entitled: "Drug delivery via therapeutic hydrogels."

The technology can be used as a drug-delivery platform involving the retention of a drug within liposomes that are microscopic spheres of lipid designed to act as time-release drug depots, according to a company news release.

The medical devices that may benefit from the technology include wound dressings, implantable medical devices and wound closure systems useful for helping to reduce hospital acquired infection, officials said.

The type of therapeutic agent that can be encapsulated within the liposomes is not restricted to a single type of antiseptic or combination of these, officials said.

The hydrogel composition might comprise a variety of active agents and include antibiotics, hormones, growth factors and other factors that are beneficial for the medical condition under management.

The issued patents augment Covalon's technology position in the expanding area of convergent medical devices, officials said.

Covalon is a Mississauga, Ont., company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.